REG - BioVentix PLC - Director/PDMR Shareholding

BioventixAnnouncement

31/03/2023 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230331:nRSe0016Va&default-theme=true

RNS Number : 0016V  BioVentix PLC  31 March 2023

Bioventix plc

("Bioventix" or the "Company")

 

Director/PDMR Shareholding

 

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, was notified on 31 March 2023 of the following
transactions in its ordinary shares of 5 pence each ("Ordinary Shares"):

 

 Director                                      Role                    Ordinary Shares sold  Average sale price per Ordinary Share  Ordinary Shares subsequently held  Percentage of issued share capital subsequently held
 Ian Nicholson and Persons Closely Associated  Non-Executive Chairman  2,500                 3,900                                  13,000                             0.2%

 

The notifications below, which have been made in accordance with the
requirements of the Market Abuse Regulation, provide further details.

 

 

For further information please contact:

 Bioventix plc                                      Tel: 01252 728 001

 Peter Harrison           Chief Executive Officer

 Bruce Hiscock            Chief Financial Officer

 finnCap Ltd                                        Tel: 020 7220 0500

 Geoff Nash/Simon Hicks   Corporate Finance

 Alice Lane               ECM

 

 

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 1   Details of the person discharging managerial responsibilities ("PDMR") /
     person closely associated ("PCA")
 a)  Name                                                         Ian Nicholson
 2.  Reason for the Notification
 a)  Position/status                                              Chairman
 b)  Initial notification/Amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Bioventix plc
 b)  LEI                                                          213800225MHX7LZQY108
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary Shares of 5 pence each
     Identification code                                          GB00B4QVDF07
 b)  Nature of the transaction                                    Sale of Ordinary Shares
 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                  3,877p    1,000
 d)  Aggregated information:                                      See 4(c)

     ·      Aggregated volume

     ·      Price
 e)  Date of the transaction                                      31 March 2023
 f)  Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

d)

Aggregated information:

·      Aggregated volume

·      Price

See 4(c)

e)

Date of the transaction

31 March 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 1   Details of the person discharging managerial responsibilities ("PDMR") /
     person closely associated ("PCA")
 a)  Name                                                         Catherine Nicholson
 2.  Reason for the Notification
 a)  Position/status                                              PCA of Ian Nicholson, Chairman
 b)  Initial notification/Amendment                               Initial notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Bioventix plc
 b)  LEI                                                          213800225MHX7LZQY108
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the Financial instrument, type of instrument  Ordinary Shares of 5 pence each
     Identification code                                          GB00B4QVDF07
 b)  Nature of the transaction                                    Sale of Ordinary Shares
 c)  Price(s) and volume(s)                                       Price(s)  Volume(s)
                                                                  3,915p    1,500
 d)  Aggregated information:                                      See 4(c)

     ·      Aggregated volume

     ·      Price
 e)  Date of the transaction                                      31 March 2023
 f)  Place of the transaction                                     London Stock Exchange, AIM Market (XLON)

d)

Aggregated information:

·      Aggregated volume

·      Price

See 4(c)

e)

Date of the transaction

31 March 2023

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEADDFDLFDEFA